Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.
作者信息
Urban C, Mariano N, Rahal J J, Tay E, Ponio C, Koprivnjak T, Weiss J
机构信息
Infectious Diseases Section The New York Hospital Medical Center of Queens Flushing, New York.
出版信息
Antimicrob Agents Chemother. 2001 Mar;45(3):994-5. doi: 10.1128/AAC.45.3.994-995.2001.
Abstract
摘要
相似文献
1
Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.
Antimicrob Agents Chemother. 2001 Mar;45(3):994-5. doi: 10.1128/AAC.45.3.994-995.2001.
2
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
J Antimicrob Chemother. 2017 May 1;72(5):1415-1420. doi: 10.1093/jac/dkx002.
3
Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii.
J Antimicrob Chemother. 2006 Jul;58(1):95-100. doi: 10.1093/jac/dkl145. Epub 2006 Apr 24.
4
Synergistic effect between nisin and polymyxin B against pandrug-resistant and extensively drug-resistant Acinetobacter baumannii.
Int J Antimicrob Agents. 2019 May;53(5):663-668. doi: 10.1016/j.ijantimicag.2019.03.009. Epub 2019 Mar 14.
5
In vitro activity of polymyxin B against carbapenem-resistant Acinetobacter baumannii.
J Med Assoc Thai. 2014 Dec;97(12):1254-8.
6
Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action.
Antimicrob Agents Chemother. 2006 Apr;50(4):1251-6. doi: 10.1128/AAC.50.4.1251-1256.2006.
7
Polymyxin Resistance Among XDR ST1 Carbapenem-Resistant Clone Expanding in a Teaching Hospital.
Front Microbiol. 2021 Mar 26;12:622704. doi: 10.3389/fmicb.2021.622704. eCollection 2021.
8
Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii.
J Antibiot (Tokyo). 2016 Jun;69(6):415-21. doi: 10.1038/ja.2015.127. Epub 2015 Dec 16.
9
Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Using Checkerboard Information.
Microb Drug Resist. 2019 Nov;25(9):1266-1274. doi: 10.1089/mdr.2018.0283. Epub 2019 Jun 19.
10
Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR : a retrospective cohort study.
Antimicrob Resist Infect Control. 2018 Jan 19;7:8. doi: 10.1186/s13756-018-0305-5. eCollection 2018.
引用本文的文献
1
Molecular typing, and integron and associated gene cassette analyses in strains isolated from clinical samples.
Exp Ther Med. 2020 Sep;20(3):1943-1952. doi: 10.3892/etm.2020.8911. Epub 2020 Jun 19.
2
Integrative analysis of outer membrane vesicles proteomics and whole-cell transcriptome analysis of eravacycline induced Acinetobacter baumannii strains.
BMC Microbiol. 2020 Feb 11;20(1):31. doi: 10.1186/s12866-020-1722-1.
3
Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy.
J Microbiol. 2017 Nov;55(11):837-849. doi: 10.1007/s12275-017-7288-4. Epub 2017 Oct 27.
4
Molecular Epidemiology and Clinical Impact of Acinetobacter calcoaceticus-baumannii Complex in a Belgian Burn Wound Center.
PLoS One. 2016 May 25;11(5):e0156237. doi: 10.1371/journal.pone.0156237. eCollection 2016.
5
High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma.
Ther Drug Monit. 2012 Aug;34(4):398-405. doi: 10.1097/FTD.0b013e31825c827a.
6
The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A.
Antimicrob Agents Chemother. 2011 Aug;55(8):3743-51. doi: 10.1128/AAC.00256-11. Epub 2011 Jun 6.
7
Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2010 Nov;54(11):4678-83. doi: 10.1128/AAC.00497-10. Epub 2010 Aug 16.
8
Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia.
Eur J Clin Microbiol Infect Dis. 2010 May;29(5):527-31. doi: 10.1007/s10096-010-0890-6. Epub 2010 Feb 25.
9
Acinetobacter baumannii: emergence of a successful pathogen.
Clin Microbiol Rev. 2008 Jul;21(3):538-82. doi: 10.1128/CMR.00058-07.
10
Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California.
J Clin Microbiol. 2008 Aug;46(8):2499-507. doi: 10.1128/JCM.00367-08. Epub 2008 Jun 4.
本文引用的文献
1
Acinetobacter.
Semin Respir Crit Care Med. 2000;21(4):341-8. doi: 10.1055/s-2000-9858.
2
Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium.
Clin Infect Dis. 1999 Apr;28(4):916-7. doi: 10.1086/517243.
3
In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak.
Antimicrob Agents Chemother. 2000 Apr;44(4):1035-40. doi: 10.1128/AAC.44.4.1035-1040.2000.
4
Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
Clin Infect Dis. 1999 May;28(5):1008-11. doi: 10.1086/514732.
5
Peptide antibiotics.
Antimicrob Agents Chemother. 1999 Jun;43(6):1317-23. doi: 10.1128/AAC.43.6.1317.
6
Bactericidal/permeability-increasing protein (rBPI21) in patients with hemorrhage due to trauma: results of a multicenter phase II clinical trial. rBPI21 Acute Hemorrhagic Trauma Study Group.
J Trauma. 1999 Apr;46(4):667-76; discussion 676-7. doi: 10.1097/00005373-199904000-00018.
7
Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis.
Lancet. 1997 Nov 15;350(9089):1439-43. doi: 10.1016/s0140-6736(97)06468-4.
8
Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.
Clin Microbiol Rev. 1996 Apr;9(2):148-65. doi: 10.1128/CMR.9.2.148.
9
Antiendotoxin activity of cationic peptide antimicrobial agents.
Infect Immun. 1996 Dec;64(12):4922-7. doi: 10.1128/iai.64.12.4922-4927.1996.
10
Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine.
Infect Immun. 1993 Jul;61(7):2978-84. doi: 10.1128/iai.61.7.2978-2984.1993.
Zotero 插件